The main update is balance-sheet repair, not an operating beat. The market already knew about the Eli Lilly milestone and the 500%+ fiscal-2027 revenue-growth target from the company’s July disclosures; this filing mainly packages the July cash events and confirms that they restored compliance with Nasdaq’s $2.5 million stockholders’ equity requirement. The filing does not provide new revenue, earnings, or contract bookings to show that the growth target is being achieved. (Listing compliance update; Preliminary Financial Information)
| Metric | Filing figure | Comparison / expectation |
|---|---|---|
| Eli Lilly milestone payment | $5.0 million | Cash received in July; previously disclosed (Preliminary Financial Information) |
| Escrow cash released | $1.0 million | Additional July liquidity (Preliminary Financial Information) |
| Financing gross proceeds | $4.0 million | Issued at $0.85 per underlying share (Preliminary Financial Information) |
| Financing net proceeds | Approximately $3.6 million | After offering costs (Preliminary Financial Information) |
| Cash on hand, August 3, 2026 | Approximately $10.1 million | Updated post-financing liquidity (Preliminary Financial Information) |
| Common shares outstanding, June 30, 2026 | 3,194,295 | Before the July warrant exercises (Preliminary Financial Information) |
| Common shares outstanding, August 3, 2026 | 13,390,789 | Up 9,896,718 shares from warrant exercises (Preliminary Financial Information) |
| Fiscal-2027 revenue guidance | 500%+ growth | Reiterated, not raised (Preliminary Financial Information) |
Funding materially improves near-term solvency, but the equity cost is substantial. The company has identified roughly $9.6 million of July cash inflows from the Lilly payment, escrow release, and financing net proceeds, and it has regained Nasdaq compliance. That is clearly better than the pre-update liquidity and listing-risk picture. But shares outstanding increased from 3.2 million at June 30 to 13.4 million by August 3, a more than fourfold increase, so much of the balance-sheet improvement came alongside significant dilution. (Preliminary Financial Information)
The revenue outlook is unchanged and remains execution-dependent. Management still expects revenue growth of more than 500% in fiscal 2027, but the filing offers no new quarterly revenue figure, customer contract value, or evidence that converts the target into a more measurable forecast. With fiscal-2026 revenue having been only about $131,000, the percentage target starts from a very small base; the filing does not establish how much of the expected growth is contracted or recurring. (Preliminary Financial Information; Fiscal 2026 Form 10-K)
Net: a meaningful financial-risk improvement, offset by dilution and no incremental business proof. Relative to the standing expectation, this is best read as confirmation of already-public financing and milestone news plus a positive compliance resolution—not a fresh earnings surprise. The cash cushion and removal of the Nasdaq equity deficiency are constructive, but the unchanged guidance and sharp share-count expansion keep the overall signal mixed.
Read the original 8-K on SEC EDGAR ↗